Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study Evaluating the Safety of NovoPen®3 and FlexPen® in Subjects With Type 1 and Type 2 Diabetes. A 24-week, Prospective, Multi-centre, Open-labelled, Non-interventional Study

NCT01454024 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01454024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01454024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study Evaluating the Safety of NovoPen®3 and FlexPen® in Subjects With Type 1 and Type 2 Diabetes. A 24-week, Prospective, Multi-centre, Open-labelled, Non-interventional Study
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Completed
Start date
November 30, 2011
Completion date
October 31, 2012
Enrollment
1,031 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

delivery systems, diabetes, diabetes mellitus, type 1, diabetes mellitus, type 2